Efficacy and Safety of Berberine in the Treatment of Diabetes With Dyslipidemia

This study has been completed.
Sponsor:
Information provided by:
Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier:
NCT00462046
First received: April 16, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted

April 16, 2007
April 16, 2007
April 2005
Not Provided
  • Fasting glucose levels
  • OGTT 2h glucose levels
  • HbA1c
  • Serum Triglycerides
  • Serum Total Cholesterol
  • HDL-c
  • LDL-c
Same as current
No Changes Posted
  • Glucose Disposal Rate
  • BMI
  • Blood pressure
Same as current
Not Provided
Not Provided
 
Efficacy and Safety of Berberine in the Treatment of Diabetes With Dyslipidemia
The Efficacy and Safety of Berberine in the Treatment of Type 2 Diabetes With Dyslipidemia

Berberine has showed effective in lowering blood sugar levels in db/db mice and anti-dyslipidemia in human. These findings have not been tested in a clinical trial. This randomized, double blind, placebo controlled and multi-center study has demonstrated that berberine is effective in lowering plasma glucose concentrations, reducing serum HbA1c and anti-dyslipidemia in type 2 diabetic patients with dyslipidemia.

Berberine, a natural plant alkaloid, has not been well investigated for clinical application in the treatment of diabetes. The present study evaluated the efficacy and safety of berberine in the treatment of type 2 diabetic patients with dyslipidemia. 116 patients with type 2 diabetes and dyslipidemia were assigned in a randomized, double-blind, and placebo-controlled 4-clinical center study to receive berberine (1.0g daily) or placebo for 3 months. The primary efficacy outcomes were changes in plasma glucose and serum lipid levels. The glucose disposal rate (GDR) was measured using a hyperinsulinemic euglycemic clamp to assess insulin resistance in a randomly selected subjects of 54 patients. The baseline characteristics were similar in berberine and placebo groups. After 3 months, fasting and post load plasma glucose levels, HbA1C, triglyceride, total cholesterol and LDL-C levels were all significantly reduced in the berberine group compared with the placebo group (p<0.0001, p<0.0001, p<0.0001, p=0.002, p<0.0001 and p<0.0001 respectively). The GDR was significantly increased after 3 months of berberine (p=0.037), while no change was found in the placebo group (p=0.86). BMI, systolic blood pressure and serum IL-6 levels were all significantly reduced after treatment in berberine group as compared with the placebo group (p=0.016, p=0.041 and p=0.014, respectively). Our results show berberine to be effective and safe in the treatment of persons with diabetes and dislipidemia. This agent may be useful in the treatment of patients with type 2 diabetes, and could play a role in treatment of metabolic syndrome.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Diabetes Mellitus, Type 2
  • Metabolic Syndrome
Drug: Berberine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
September 2006
Not Provided

Inclusion Criteria:

  1. Age of 25 -70 years;
  2. Newly diagnosed type 2 diabetes according to the 1999 World Health Organization criteria;
  3. Dyslipidemia with TG> 150mg/dL (1.70mmol/L), and/or TC>200mg/dL (5.16mmol/L), and/or LDL-C>100mg/dL (2.58mmol/L) according to the National Cholesterol Education Program’s Adult Treatment Panel III (NCEP: ATPIII) without previous treatment.
  4. BMI:19 – 40 kg/m2.

Exclusion Criteria:

  1. Moderate or severe liver or renal dysfunction, psychiatric disease or severe infection;
  2. Severe dysfunction of the heart,New York Heart Association class ³ Ⅲ phase;
  3. History of acute diabetic complications;
  4. Pregnancy or planned pregnancy.
  5. Present or previous use of drugs for treatment of diabetes or dyslipidemia;
  6. Fasting plasma glucose >8mmol/L and/or post load plasma glucose level >17mmol/L after 2-week run-in.
Both
25 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00462046
CCEMD001
Yes
Not Provided
Shanghai Jiao Tong University School of Medicine
Not Provided
Principal Investigator: Xiao-Ying Li, MD,PhD Shanghai Jiao Tong University School of Medicine
Shanghai Jiao Tong University School of Medicine
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP